{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=7",
    "query": {
      "intervention": "Placebo (treatment C)",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 989,
    "total_pages": 99,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:03:32.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05956509",
      "title": "Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Upper Limb Spasticity"
      ],
      "interventions": [
        {
          "name": "ABBV-950",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BOTOX",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for ABBV-950",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1,
      "start_date": "2024-01-12",
      "completion_date": "2024-06-02",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 9,
      "location_summary": "Carlsbad, California • Downey, California • Fresno, California + 6 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05956509"
    },
    {
      "nct_id": "NCT03827798",
      "title": "Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "CFZ533",
          "type": "DRUG"
        },
        {
          "name": "Placebo to CFZ533",
          "type": "DRUG"
        },
        {
          "name": "LYS006",
          "type": "DRUG"
        },
        {
          "name": "Placebo to LYS006",
          "type": "DRUG"
        },
        {
          "name": "MAS825",
          "type": "DRUG"
        },
        {
          "name": "Placebo to MAS825",
          "type": "DRUG"
        },
        {
          "name": "LOU064 25mg",
          "type": "DRUG"
        },
        {
          "name": "LOU064 100mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to LOU064",
          "type": "DRUG"
        },
        {
          "name": "VAY736",
          "type": "DRUG"
        },
        {
          "name": "Placebo to VAY736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 248,
      "start_date": "2019-02-27",
      "completion_date": "2026-12-11",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 8,
      "location_summary": "Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03827798"
    },
    {
      "nct_id": "NCT03905525",
      "title": "Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjögren Syndrome"
      ],
      "interventions": [
        {
          "name": "CFZ533",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 273,
      "start_date": "2019-10-01",
      "completion_date": "2023-06-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 8,
      "location_summary": "Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more",
      "locations": [
        {
          "city": "Suwanee",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03905525"
    },
    {
      "nct_id": "NCT00910962",
      "title": "A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "GW856553",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 526,
      "start_date": "2009-10-08",
      "completion_date": "2012-03-06",
      "has_results": true,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 30,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00910962"
    },
    {
      "nct_id": "NCT01465815",
      "title": "Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Skin Cancer",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Squamous Cell Carcinoma of the Skin",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "linsitinib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "therapeutic conventional surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-12",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-11-19",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465815"
    },
    {
      "nct_id": "NCT03509285",
      "title": "A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Alprazolam Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cenobamate placebo",
          "type": "DRUG"
        },
        {
          "name": "Alprazolam",
          "type": "DRUG"
        },
        {
          "name": "Cenobamate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SK Life Science, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 53,
      "start_date": "2017-03-08",
      "completion_date": "2017-12-15",
      "has_results": false,
      "last_update_posted_date": "2024-11-07",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03509285"
    },
    {
      "nct_id": "NCT06111586",
      "title": "Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Frexalimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 197,
      "start_date": "2023-12-11",
      "completion_date": "2030-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 14,
      "location_summary": "San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111586"
    },
    {
      "nct_id": "NCT05330182",
      "title": "LMN-201 for Prevention of C. Difficile Infection Recurrence",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Clostridioides Difficile Infection"
      ],
      "interventions": [
        {
          "name": "LMN-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lumen Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2024-08-29",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 15,
      "location_summary": "Escondido, California • Hamden, Connecticut • Tampa, Florida + 12 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Burr Ridge",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330182"
    },
    {
      "nct_id": "NCT01593605",
      "title": "Resveratrol-Leucine Metabolite Synergy in Pre-diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Resveratrol",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "resveratrol /HMB",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-02",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01593605"
    },
    {
      "nct_id": "NCT00043537",
      "title": "Treatment of Childhood Social Phobia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Social Phobia"
      ],
      "interventions": [
        {
          "name": "Social Effectiveness Therapy for Children (SET-C)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Fluoxetine",
          "type": "DRUG"
        },
        {
          "name": "Pill Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "8 Years to 16 Years"
      },
      "enrollment_count": 139,
      "start_date": "2001-04",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2013-08-01",
      "last_synced_at": "2026-10-14T16:03:32.767Z",
      "location_count": 1,
      "location_summary": "University of Maryland, College Park, Maryland",
      "locations": [
        {
          "city": "University of Maryland, College Park",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00043537"
    }
  ]
}